Keyphrases
Lymphoma Patients
100%
Bone Mass
100%
Anti-CD20
100%
Bone Preservation
100%
Bone Mass Increase
100%
B-cell Depletion
100%
Bone Mineral Density
50%
Maintenance Therapy
50%
Rituximab
50%
Positron Emission Tomography-computed Tomography (PET-CT)
50%
Conflicting Results
25%
Specific Antibodies
25%
B Cells
25%
Cell-derived
25%
Antitumor Activity
25%
Bone Marrow Cells
25%
Bone Remodeling
25%
Follicular Lymphoma
25%
C57BL
25%
Autoimmune Disease
25%
Standard of Care
25%
X-ray Imaging
25%
Femur
25%
Female Mice
25%
Cortical Tissue
25%
Anti-CD20 Antibody
25%
Trabecular Bone Tissue
25%
B-cell Lymphoproliferative Disorder
25%
Imaging CT
25%
Active Maintenance
25%
Rituximab Maintenance
25%
Murine Studies
25%
Anti-CD20 Treatment
25%
Tissue Mineral Density
25%
Medicine and Dentistry
B Cell
100%
Bone Mass
100%
CD20
100%
Rituximab
60%
Bone Density
40%
Maintenance Therapy
40%
Follicular Lymphoma
20%
Lymphoproliferative Disease
20%
Autoimmune Disease
20%
Immunotherapy
20%
Osteoplasty
20%
Osteoclast Differentiation Factor
20%
Positron Emission Tomography-Computed Tomography
20%
Antineoplastic Activity
20%
CD20 Antibody
20%
Mineral Density
20%
Bone Remodeling
20%
Bone Marrow Cell
20%
Immunology and Microbiology
CD20
100%
B Cell
100%
Bone Mass
100%
Rituximab
60%
Bone Density
40%
Bone Marrow Cell
20%
Autoimmune Disease
20%
X Ray
20%
Immunotherapy
20%
Antineoplastic Activity
20%
RANKL
20%
Positron Emission Tomography-Computed Tomography
20%
Bone Remodeling
20%
Lymphoproliferative Disorders
20%
CD20 Antibody
20%